POPULARITY
Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, says the company looks for honest unmet needs when deciding what targets to explore. It also looks for opportunities to be the first or the best.The company may meet both objectives with TP-03, an antiparasitic agent developed to treat Demodex blepharitis, among other conditions.Mottiwala describes lotilaner, the molecule behind TP-03 and other Tarsus therapies, as a “pipeline in a molecule.” The company is evaluating formulations of lotilaner for the treatment of Lyme disease and rosacea as well as Demodex blepharitis.With podcast host Carey Powers, Mottiwala and Bill Link, PhD, Managing Director of Versant Ventures and leader of the firm's ophthalmology venture category, discuss how to execute successful direct-to-consumer campaigns, including the “eyelid check” campaign for Demodex blepharitis.They also discuss the investment outlook for eye care. With funding harder to come by, start-ups may want to take note of how Dr. Link evaluates companies, which he discusses in this episode. Hint: strong science and a solid business plan are not enough.Listen to the podcast today to discover:The five categories Dr. Link uses to evaluate an eye care company.Whether AI-based technologies are an attractive investment.How Tarsus evaluates opportunities in the pipeline.The Tarsus approach to DTC for TP-03 and why patients aren't the initial focus.How 2023 is shaping up for investment and access to capital.Innovation Mottiwala is excited about and how Tarsus may integrate new technology into their commercial activities.How technology is impacting how Tarsus builds its organization.[Listen Now]ResourcesDemodex blepharitis campaign: https://eyelidcheck.comBill Link: https://www.versantventures.com/team/bill-link-phdAziz Mottiwala: https://www.linkedin.com/in/azizmottiwalaCarey Powers: https://ois.net/carey-powers
Nicholas Curtis, CEO of LENSAR, got some of his entrepreneurial spirit seeing his grandfathers (“pappous” in their Greek homeland) and father own and operate bars and restaurants. A football scholarship took him to Northwestern University in Chicago, and the rest has been what he calls “a circuitous route, with some serendipity.”Curtis traces his route in this episode of the OIS podcast, through his first job, at IBM, where he was trained in the company’s philosophy of a needs satisfaction approach to selling. He said, “It was all about building a relationship, and ultimately earning the right to ask for the business.”That position led to one with American Hospital Supply, where Curtis met Bill Link, (now Managing Partner of Flying L Partners), who became president of American Medical Optics (AMO) and recruited Curtis to join him. Curtis later joined Lensar as chief commercial officer, and was named “interim” CEO in 2012. Lensar is currently developing the Ally system, which Curtis says is “the first femtosecond laser for cataract surgery that integrates a next-gen laser with a Swiss-engineered phaco-emulsification device in a very small compact cataract treatment removal system.” The company is looking to file a 510K early in 2022, and hopes to bring the product to market in the 2nd part of 2022. Curtis also discusses tips for being successful including:Teamwork is important, members should share corporate valuesSurround yourself with good peopleHave respect for different points of viewAlways have integrityBe customer focused, meet customer needTreat customers as partnersDon’t be afraid of making a mistake, but moving on is criticalClick play to hear Nick Curtis describe his ongoing business path!
OIS Israel Co-Chair William J. Link, PhD, of Flying L Partners, shares some business life lessons and the unique sequence of events that led him into ophthalmology and eventually venture capital. Dr. Link also discusses the impact of COVID-19 on his portfolio companies and predictions on when and how we as an industry will come out of this. Don’t miss this highly informative and entertaining discussion between Ehsan Sadri, MD, and the man he calls “the Phil Jackson of ophthalmology.”
Class 3 from Bro. Bill Link’s series on Portraits of the Master. Class 1 from this series was used for GCT Episode 038.
Class 1 from Bro. Bill Link’s series on Portraits of the Master. Class 1 from this series was used for GCT Episode 038.
Class 2 from Bro. Bill Link’s series on Portraits of the Master. Class 1 from this series was used for GCT Episode 038.
Class 4 from Bro. Bill Link’s series on Portraits of the Master. Class 1 from this series was used for GCT Episode 038.
Class 5 from Bro. Bill Link’s series on Portraits of the Master. Class 1 from this series was used for GCT Episode 038.
Class 6 from Bro. Bill Link’s series on Portraits of the Master. Class 1 from this series was used for GCT Episode 038.
Class 7 from Bro. Bill Link’s series on Portraits of the Master. Class 1 from this series was used for GCT Episode 038.
Today we are listening to a talk by Bro. Bill Link that was given at the Idylwild Bible School in 2017 from his series title “Portraits of the Master”, this is Class 1 “The Hands of the Master.” Thank you for listening, God bless, and talk to you next week. Send talk suggestions or comments to: GoodChristadelphianTalks@gmail.com For Show Notes, visit our website: Anchor.fm/GCT Social Media: Facebook | Instagram | Twitter
Nails & Tracey's chat aimed towards Audio Presenters. #2 - Fired From your Radio Show - What do you do? Channel 4 104.4 in Dubai is bursting with Good Talent (JJ Thompson, Jacob & Nimi). Morning Show gals, Liz & Reilly (94.5 Mix FM, Oregon, USA) are put on the spot with 3 Questions for Boom TV. OnAirCoach chats to Mike Russell (Music Radio Creative) and..That Broadway Bill Link!! @onaircoach.net
Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, co-chairs of OIS, talk about device funding, myopia, and the Masters of the Industry following a successful OIS@ASCRS.
OIS Co-Chair William J. Link, PhD walks us through OIS@ASCRS’ May 4 agenda, which takes place in LA. Link also explains why he Andy Corley and Richard Lindstrom, MD, formed Flying L Partners. Hear about the firm’s most recent investment.
[00:00] Intro Let's News! [06:52] Duke Nukem 3D Re-release? [LINK] [17:31] Newseum Network News and the existential dispair of Bill [LINK] [20:22] Overwatch: Sombra still a no show, and the mysterious Sombra AGR [LINK] [LINK 2] [27:27] Ridin' the .wav [33:47] Commercials SPOILERS BE HERE! [37:35] Haphazard Mr. Robot Recap [47:35] Stargate SG-1 S01E15 - Cor-Ai Recap [56:56] Stargate SG-1 S01E16 - Enigma Recap [64:07] Stargate SG-1 S01E17 - Solitudes Recap
Live from the floor of OIS@ASRS: Co-chair Bill Link on what made the day work so well. The marriage of OIS with ASRS started strong. Hear ophthalmology veteran Bill Link on why the back of the eye is an enormous opportunity for companies, investors, and physicians.
Bill Link, Managing Director at Versant Ventures, explains why opthalmology will continue to be a pillar for Versant's new fund. He also gives helpful advice to entrepreneurs and physicians looking to turn inspiration into innovation.